Irbesartan
irbesartan · Brand: Avapro
Irbesartan Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults | Monotherapy or combination | FDA Approved |
| Diabetic nephropathy — in T2DM with hypertension, elevated serum creatinine, and proteinuria (>300 mg/day) | Adults with type 2 diabetes | Part of antihypertensive regimen; reduces progression of nephropathy (doubling of SCr, ESRD) | FDA Approved |
Irbesartan stands out among ARBs for its strong evidence base in diabetic kidney disease. The IDNT trial (NEJM 2001) demonstrated a 20% reduction in the composite renal endpoint (doubling of serum creatinine, ESRD, or death) compared to placebo (p=0.02) and a 23% reduction compared to amlodipine (p=0.006) in patients with overt type 2 diabetic nephropathy. Irbesartan also slowed the rate of doubling of serum creatinine by 24% compared to placebo (p=0.008) and by 21% compared to amlodipine (p=0.02). The IRMA 2 trial (NEJM 2001) showed that irbesartan 300 mg reduced the risk of progression from microalbuminuria to overt nephropathy by 70% — only 5.2% of patients in the 300 mg group progressed compared to 14.9% in the placebo group (HR 0.30, p<0.001). This benefit was independent of blood pressure lowering, confirming a specific renoprotective effect.
Diabetic nephropathy with microalbuminuria (early-stage): The IRMA 2 trial demonstrated renoprotection in T2DM patients with microalbuminuria, but the FDA-approved nephropathy indication requires overt proteinuria (>300 mg/day). Use in the microalbuminuria stage is supported by guideline recommendations (KDIGO 2024, ADA 2025) for ARBs as a class. Evidence quality: High (IRMA 2 trial).
Heart failure as ACE inhibitor alternative: ARBs including irbesartan are recommended by AHA/ACC/HFSA guidelines as alternatives to ACE inhibitors in HFrEF patients who are intolerant. Irbesartan does not hold a specific HF indication. Evidence quality: High (class effect).
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — standard initiation | 150 mg once daily | 150–300 mg once daily | 300 mg/day | Antihypertensive effect apparent after first dose; close to full observed effect at 2 weeks May be administered with or without food; no food-related dose adjustment |
| Hypertension — volume or salt-depleted patient | 75 mg once daily | 150–300 mg once daily | 300 mg/day | Includes patients on high-dose diuretics or hemodialysis; correct volume depletion before starting Titrate once volume status is stabilised |
| Diabetic nephropathy — T2DM with proteinuria | 150 mg once daily | 300 mg once daily (target dose) | 300 mg/day | Target dose of 300 mg daily is the IDNT-studied dose; titrate from 150 mg as tolerated Additional antihypertensives may be added (excluding ACEi, ARB, or CCB per IDNT protocol) |
Irbesartan has the highest oral bioavailability (60–80%) among commonly used ARBs, and food does not affect its absorption — a significant practical advantage over valsartan (whose exposure drops by ~40% with food). The long half-life of 11–15 hours supports reliable once-daily dosing with sustained 24-hour AT1 blockade. The simple three-strength tablet range (75, 150, 300 mg) and absence of renal dose adjustment streamline prescribing. For the diabetic nephropathy indication, the clinical evidence specifically supports 300 mg/day as the target dose (IDNT); there are no outcome data for lower doses in this setting. Irbesartan is not a prodrug, so its activity does not depend on hepatic CYP-mediated conversion.
Pharmacology
Mechanism of Action
Irbesartan is a non-peptide, orally active, selective angiotensin II type 1 (AT1) receptor antagonist. It blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II by non-competitively binding the AT1 receptor in vascular smooth muscle, adrenal cortex, kidney, and other tissues. Irbesartan has no agonist activity at the AT1 receptor and has essentially no affinity for the AT2 receptor. Unlike losartan, irbesartan is not a prodrug — the parent compound is pharmacologically active and does not require hepatic activation. It does not inhibit ACE (kininase II), so bradykinin is not accumulated, resulting in a cough profile essentially identical to placebo (2.8% vs 2.7%). Blockade of AT1 receptors interrupts negative feedback on renin secretion, leading to elevated plasma renin and angiotensin II levels, but these do not overcome receptor blockade. There is essentially no change in heart rate with irbesartan treatment.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability 60–80%; Tmax 1.5–2 h; food does not affect bioavailability; linear pharmacokinetics across therapeutic dose range | Highest bioavailability among common ARBs; no food-timing instructions needed — major practical advantage; predictable dose-response relationship |
| Distribution | Vd 53–93 L; protein binding 90% (albumin and α1-acid glycoprotein); weakly crosses blood-brain barrier; crosses placenta in animals; excreted in milk of lactating rats | Moderate tissue distribution; not removed by haemodialysis despite moderate protein binding; no dose adjustment for renal impairment |
| Metabolism | Not a prodrug; >80% circulating radioactivity is unchanged irbesartan; metabolised via glucuronide conjugation and CYP2C9-mediated oxidation; CYP3A4 negligible; primary metabolite is inactive glucuronide conjugate (~6% of dose) | Active parent compound — no reliance on CYP-mediated activation; CYP2C9 polymorphisms may increase exposure (1.6–1.8-fold higher AUC in CYP2C9*3 carriers) but clinical dose adjustment is not routinely recommended |
| Elimination | t½ 11–15 h; ~20% excreted in urine, remainder in faeces (biliary + renal routes); total clearance 157–176 mL/min; renal clearance 3.0–3.5 mL/min; steady state in 3 days; <20% accumulation; not removed by haemodialysis | Longest half-life among commonly used ARBs — supports true once-daily dosing; biliary excretion predominant; PK not altered by renal impairment or mild-moderate hepatic impairment |
Side Effects
Irbesartan has been evaluated for safety in more than 4,300 hypertensive patients and approximately 5,000 subjects overall, including 1,303 treated for over 6 months and 407 for one year or more. In hypertension trials, the side effect profile was close to placebo. The diabetic nephropathy population (IDNT) demonstrated a distinct adverse effect profile driven by higher rates of hyperkalemia and orthostatic symptoms due to the underlying renal disease and concomitant medications.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hyperkalemia (K+ >6 mEq/L) | 18.6% (vs 6.0% placebo) | Major concern in nephropathy population; related to RAAS blockade in setting of renal impairment; discontinuation for hyperkalemia 2.1% vs 0.4% placebo |
| Dizziness | 10.2% (vs 6.0% placebo) | Most common symptomatic adverse effect in IDNT; dose-related; usually manageable |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Orthostatic dizziness (IDNT) | 5.4% (vs 2.7% placebo) | More common in nephropathy patients; advise slow positional changes; assess volume status |
| Orthostatic hypotension (IDNT) | 5.4% (vs 3.2% placebo) | Monitor especially with concomitant diuretics; reduce diuretic dose if symptomatic |
| Fatigue (HTN) | 4% (vs 3% placebo) | Marginally above placebo; evaluate for excessive BP reduction if persistent |
| Diarrhoea (HTN) | 3% (vs 2% placebo) | Generally self-limiting; no dose adjustment required |
| Cough | 2.8% (vs 2.7% placebo) | Essentially identical to placebo — best cough profile among all ARBs; ideal for ACEi-intolerant patients with cough |
| Dyspepsia / heartburn (HTN) | 2% (vs 1% placebo) | Mild GI effect; take with food if bothersome |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hyperkalemia requiring discontinuation (IDNT) | 2.1% (vs 0.4% placebo) | Weeks to months | Hold irbesartan if K+ >5.5 mEq/L; treat hyperkalemia; reassess need for continued therapy; monitor more frequently after reinitiation |
| Angioedema (postmarketing) | Rare | Any time | Discontinue immediately; emergency airway management; never rechallenge; includes intestinal angioedema |
| Anaphylactic reaction (postmarketing) | Very rare | Any time | Emergency treatment; permanent discontinuation |
| Acute renal failure | Uncommon | Days to weeks | Discontinue or reduce dose; evaluate for renal artery stenosis or volume depletion; monitor creatinine closely |
| Hepatitis / jaundice (postmarketing) | Very rare | Variable | Discontinue; monitor LFTs; consider alternative antihypertensive class |
| Thrombocytopenia (postmarketing) | Very rare | Variable | Discontinue; monitor platelet count; investigate other causes |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Hyperkalemia (IDNT) | 2.1% (vs 0.4% placebo) | Population with renal impairment at baseline; K+ >6 mEq/L in 18.6% of patients; monitor closely |
| Orthostatic symptoms (IDNT) | Uncommon | Dizziness and orthostatic hypotension were common but rarely led to permanent discontinuation |
The high rate of hyperkalemia (18.6% with K+ >6 mEq/L) in the IDNT reflects the vulnerable renal population, not a unique drug effect beyond the expected RAAS blockade. Management includes dietary potassium restriction, avoidance of K-sparing agents, and regular monitoring. Mild hyperkalemia (K+ 5.0–5.5 mEq/L) may be tolerated with close surveillance given the substantial renoprotective benefit. Discontinuation should be reserved for K+ >5.5 mEq/L that does not respond to conservative measures.
Drug Interactions
Irbesartan is metabolised primarily by CYP2C9 with negligible CYP3A4 involvement. In clinical studies, no clinically significant pharmacokinetic interactions were observed with nifedipine, hydrochlorothiazide, warfarin, or digoxin. The primary interactions are pharmacodynamic, related to potassium homeostasis, renal haemodynamics, and dual RAAS blockade. In vitro data show CYP2C9 inhibitors (e.g., fluconazole) could theoretically increase irbesartan exposure, but this has not been confirmed to be clinically significant.
Monitoring
- Blood PressureEach visit; 2 weeks after initiation
RoutineAntihypertensive effect close to full observed effect at 2 weeks. At the end of an 8-week exposure, about two-thirds of the effect was still present one week after the last dose. No rebound hypertension observed upon withdrawal. - Serum PotassiumBaseline, 1–2 weeks, then regularly; more frequently in nephropathy
RoutineK+ >6 mEq/L in 18.6% of IDNT patients vs 6.0% placebo. Critical parameter in the diabetic nephropathy population. Hold if K+ >5.5 mEq/L; discontinue if persistent despite conservative measures. - Renal FunctionBaseline, 1–2 weeks, then every 3–6 months
RoutineMonitor creatinine and eGFR; an initial modest rise in creatinine (<30%) is expected with RAAS blockade and may stabilise. In the IDNT, irbesartan slowed the rate of eGFR decline over 2.6 years. Investigate if creatinine rises >30% or progressively. - Proteinuria / AlbuminuriaBaseline, then every 6–12 months in nephropathy patients
RoutineIrbesartan reduced albuminuria by 47% vs comparators in IDNT. Monitor urine albumin-to-creatinine ratio (UACR) to assess treatment response and renal progression. - Hepatic FunctionIf symptoms of hepatic injury develop
Trigger-basedVery rare postmarketing reports of hepatitis, jaundice, and elevated LFTs. Discontinue if significant hepatic impairment develops. PK not significantly altered in mild-moderate cirrhosis. - Blood Glucose (Diabetics)As per diabetes management protocol
Trigger-basedPostmarketing reports of hypoglycaemia in diabetic patients. Be aware of potential additive hypoglycaemic risk with antidiabetic agents; adjust diabetes medication if needed.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity: Known allergy to irbesartan or any component of the formulation.
- Pregnancy: Contraindicated at any stage; direct fetal toxicity (FDA Boxed Warning). Discontinue as soon as pregnancy is detected.
- Aliskiren co-administration in diabetes: Contraindicated due to increased renal, hypotensive, and hyperkalaemic risk.
Relative Contraindications (Specialist Input Recommended)
- Bilateral renal artery stenosis or stenosis of a solitary kidney: Risk of acute renal failure from loss of efferent arteriolar tone.
- Severe volume or salt depletion: Risk of symptomatic hypotension; correct depletion before initiating or use 75 mg starting dose.
- History of angioedema (especially ACEi-related): Caution recommended; some authors advise avoiding all RAAS blockers in patients with prior ACEi-induced angioedema.
Use with Caution
- Severe renal impairment: No dose adjustment per se, but 75 mg starting dose recommended for haemodialysis patients (volume-depleted).
- Severe hepatic impairment: PK not significantly affected in mild-moderate cirrhosis; however, no clinical experience in severe hepatic disease. Irbesartan is largely eliminated via the biliary route.
- Elderly (≥75 years): AUC and Cmax are 20–50% higher than in young adults; consider 75 mg starting dose.
- Black patients: Generally smaller antihypertensive response as monotherapy; addition of a diuretic improves efficacy.
When pregnancy is detected, discontinue irbesartan as soon as possible. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus, including oligohydramnios, fetal renal failure, hypotension, skull hypoplasia, and neonatal death. Breastfeeding is not recommended during irbesartan treatment.
Patient Counselling
Purpose of Therapy
Irbesartan works by blocking the effects of a hormone called angiotensin II, which narrows blood vessels and causes the body to retain salt and water. By blocking this hormone, irbesartan helps relax blood vessels and lower blood pressure. If it has been prescribed for kidney protection in diabetes, irbesartan specifically slows down kidney damage by reducing the pressure and protein leakage in the kidneys.
How to Take
Take irbesartan once daily at the same time each day. It can be taken with or without food — this does not affect how the medication works, which is a practical advantage. Do not stop taking irbesartan without consulting your doctor, even if you feel well. If you are taking it for kidney protection, achieving and maintaining the 300 mg dose is important for maximum benefit.
Sources
- Avapro (irbesartan) tablets prescribing information. Sanofi-Aventis U.S. LLC. Revised August 2025. FDA Label PDFCurrent FDA-approved prescribing information; primary source for all dosing, contraindications, adverse reactions, drug interactions, and pharmacokinetic data.
- Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi:10.1056/NEJMoa011303IDNT trial (n=1,715); demonstrated 20% reduction in composite renal endpoint vs placebo (p=0.02) and 23% vs amlodipine (p=0.006); cornerstone evidence for the diabetic nephropathy indication.
- Parving HH, Lehnert H, Bröchner-Mortensen J, et al.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. doi:10.1056/NEJMoa011489IRMA 2 trial (n=590); irbesartan 300 mg reduced progression to diabetic nephropathy by 70% vs placebo (HR 0.30, p<0.001); independently of blood pressure lowering.
- Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542–549. doi:10.7326/0003-4819-138-7-200304010-00010IDNT cardiovascular outcomes analysis; no difference in composite CV events between groups but irbesartan reduced heart failure hospitalisations vs placebo (HR 0.72, p=0.048).
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018Updated CKD guideline recommending RAAS blockade for renoprotection in diabetic albuminuria; directly supports irbesartan use in the nephropathy setting.
- American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S239–S251. doi:10.2337/dc25-S011ADA 2025 standards recommending ARBs for renoprotection in T2DM with albuminuria; specifically references IDNT and IRMA 2 evidence for irbesartan.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006US hypertension guideline positioning ARBs as first-line agents for compelling indications including CKD and diabetes.
- Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol. 1998;38(8):702–707. doi:10.1002/j.1552-4604.1998.tb04810.xFoundational PK study establishing absolute bioavailability (60–80%), lack of food effect, and linear pharmacokinetics of irbesartan.
- Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet. 2001;40(8):605–614. doi:10.2165/00003088-200140080-00004Comprehensive review of irbesartan drug interaction studies confirming absence of clinically significant PK interactions with warfarin, digoxin, HCTZ, and nifedipine.
- Chang SW, Park CH, Kim HS, et al. CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Clin Pharmacol Ther. 2011;90(2):1–6. doi:10.1038/clpt.2011.106Pharmacogenomic study demonstrating 1.6–1.8-fold higher irbesartan AUC in CYP2C9 poor metaboliser allele carriers; clinically relevant for populations with high CYP2C9 variant frequency.
- Pool JL, Guthrie RM, Littlejohn T, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998;11(4):462–470. doi:10.1016/S0895-7061(97)00494-1Dose-ranging study establishing efficacy of 150–300 mg irbesartan for blood pressure reduction; supported the recommended dose range in the FDA approval.